MAPT and Alzheimer disease: Therefore, describing the differences in tau phosphorylation level in the EC region between PART and AD, and utilizing omics analysis to uncover key proteins driving these differences, is crucial for advancing our understanding of tauopathy mechanisms and for identifying potential therapeutic targets.